WuXi PharmaTech, a pharmaceutical service provider, and Eli Lilly and Company, have formed a strategic collaboration to develop, manufacture, and commercialize a small-molecule drug candidate in China.

The drug candidate is an once-daily oral agent, discovered by Lilly, which could address cardiovascular risk in patients with dyslipidemia, The potential medicine aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events.

WuXi will be responsible for regulatory, development, and manufacturing activities in China, which will be led and coordinated by WuXi’s Product Development Service and Partnership (PDSP) Business Unit. The potential medicine will be manufactured in China by WuXi to support China development. Lilly will be responsible for commercial activities. An investigational new drug (IND) application will be filed in China by WuXi, and product development and registration will be carried out within China.

Source: WuXi PharmaTech